14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
XRN vs SBRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas SBRA carries 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin).
Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XRN vs SBRA. Trailing 12-month operating profitability (XRN N/A vs SBRA 18.4%) and valuation multiples (XRN N/M vs SBRA 30.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the REIT - Healthcare Facilities value chain with $5.4B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment31.2% of Rev ($288M)
90D Engineering Disclosures0 Published
Investor FAQ XRN vs SBRA Key Questions & Quantitative Answers
As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas SBRA carries 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin). Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SBRA leads the Growth & Scale pillar: XRN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SBRA at +31.6% YoY revenue growth and +22.2% YoY earnings growth on $924M TTM revenue (49.6% gross margin, 18.4% operating margin). On trailing 12-month operating scale, XRN generates N/A in USD-normalized revenue versus $924M for SBRA. In operating R&D and SG&A reinvestment, XRN deploys N/A (0 90-day corporate R&D disclosures) versus 31.2% of Rev ($288M) (0 disclosures) for SBRA.
SBRA screens cheaper on headline valuation multiples. XRN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SBRA trades at 30.4x Forward P/E, 75.7x Trailing P/E, 5.28x PEG, and 8.4x EV/Revenue (43.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XRN (N/A ROE) versus SBRA (2.5% ROE) capital efficiency.
In options market volatility and institutional positioning, XRN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 47% Vol realized risk). By comparison, SBRA carries 27.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.00β · 30% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.